Toxicities associated with brentuximab vedotin in pediatric and adolescent Hodgkin lymphoma

2 Views

07/09/23

Kara Kelly, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, provides an overview of the toxicities associated with brentuximab vedotin in adolescent and pediatric patients with Hodgkin lymphoma. Concerns of myelosuppression, infection risk and peripheral neuropathy which are associated with brentuximab vedotin administration in adults, is reduced in adolescent and pediatric populations. Dr Kelly discusses the next steps evaluating the use of brentuximab vedotin in pediatric settings, and highlights reduced radiotherapy as an area of unmet need in this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.